Search

Your search keyword '"Mekolli, Ardian"' showing total 7 results
Start Over Author "Mekolli, Ardian"
7 results on '"Mekolli, Ardian"'

2. IMMUTACE: A biomarker-orientated phase II, single-arm, open-label AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate-stage hepatocellular carcinoma (HCC; AIO-HEP-0217)—Updated efficacy results.

Author

Saborowski, Anna, primary, Waldschmidt, Dirk, additional, Hinrichs, Jan, additional, Ettrich, Thomas Jens, additional, Martens, Uwe Marc, additional, Mekolli, Ardian, additional, De Toni, Enrico N, additional, Berg, Thomas, additional, Geißler, Michael, additional, Hausner, Guido, additional, Maenz, Martin, additional, Ehmer, Ursula, additional, Kirstein, Marta, additional, and Vogel, Arndt, additional

Published
2022
Full Text
View/download PDF

3. Cure Is Possible: Extensively Metastatic HER2-Positive Gastric Carcinoma with 5 years of Complete Remission after Therapy with the FLOT Regimen and Trastuzumab

Author

Schade, Sebastian, primary, Koenig, Ute, additional, Mekolli, Ardian, additional, Gaedcke, Jochen, additional, Neesse, Albrecht, additional, Reinecke, Johanna, additional, Brunner, Marius, additional, Amir Hosseini, Ali Seif, additional, Kitz, Julia, additional, Stroebel, Philipp, additional, Lotz, Joachim, additional, Ghadimi, Michael, additional, Ellenrieder, Volker, additional, and Koenig, Alexander, additional

Published
2022
Full Text
View/download PDF

4. Effectiveness of fourth-line dual immunotherapy in hepatocellular carcinoma with simultaneous steroid administration for immune-related hepatitis

Author

Lowes, Kristina, primary, Reinecke, Johanna, additional, Brunner, Marius, additional, Scholz, Matthias, additional, Kitz, Julia, additional, Michels, Beate, additional, Mekolli, Ardian, additional, Gaedcke, Jochen, additional, Seif Amir Hosseini, Ali, additional, Ströbel, Philipp, additional, Ghadimi, Michael, additional, Ellenrieder, Volker, additional, Koenig, Alexander, additional, and Koenig, Ute, additional

Published
2022
Full Text
View/download PDF

7. Prophylactic endoscopic vacuum therapy for stricture prevention following wide-field endoscopic submucosal dissection of superficial esophageal cancer.

Author

Blasberg T, Meiborg M, Richl J, Weber M, Hiebel L, Mekolli A, Hosseini ASA, Amanzada A, Ellenrieder V, Hochberger J, and Wedi E

Abstract

Background and Aims: Esophageal stricture (ES) is a severe adverse event following wide-field endoscopic submucosal dissection (ESD) of superficial esophageal carcinoma. This study evaluated the efficacy and safety of combining endoscopic vacuum therapy (EVT) and budesonide orodispersible tablet (BOT) in preventing post-ESD strictures., Methods: This prospective case series included patients with superficial esophageal squamous cell carcinoma and adenocarcinoma who had wide-field ESD (≥75% circumference, resection length ≥50 mm). After ESD, EVT was applied immediately, followed by 8 weeks of BOT. The main outcome measurement was the incidence of post-ESD stricture., Results: Eleven patients underwent ESD. Of these, 81.8% had 75-99% circumference resected, and 18.2% had a circumferential resection. EVT remained in situ for a mean of 3.5 days. No esophageal strictures were observed by the final follow-up. There were no major adverse events related to EVT or BOT., Conclusions: The prophylactic combination of EVT and BOT is a novel and promising strategy for reducing post-ESD strictures., (Copyright © 2024 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results